# Vaccine Therapy in Treating Patients With Melanoma of the Eye

> **NCT00036816** · PHASE3 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 13 (actual)

## Conditions studied

- Intraocular Melanoma

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** NA17-A antigen
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00036816
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-02
- **Primary completion:** 2003-02
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036816, "Vaccine Therapy in Treating Patients With Melanoma of the Eye". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00036816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*